Neo-Adjuvant Gemcitabine and Cisplatin in Treating Patients With Early Stage of Non Small Cell Lung Cancer

Phase II Trial of Gemcitabine and Cisplatin as Neo-Adjuvant Chemotherapy for Operable Non-Small Cell Lung Cancer

Based on available data, the concept of neo-adjuvant chemotherapy seems to be promising for patients with resectable non-small cell lung cancer. The exploration of new drugs and regimens are warranted. Therefore the aim of this study is to evaluate the clinical response rate of neo-adjuvant chemotherapy with gemcitabine and cisplatin in patients with operable non-small cell lung cancer stage IB, IIA-B, IIIA.

Inclusion Criteria:

• define histologic or cytologic diagnosis of non small cell lung cancer.
• determine the presence of clinical Stage IB, IIA-B or IIIA disease in accordance with the revision by Mountain CF of American Joint Committee on Cancer.
• define performance status of 0-1 on ECOG scale
• do not have any prior tumor therapy
• to be suitable for curative resection

Exclusion Criteria:

• to have any treatment within the last 30 days with any investigational drug.
• to get concurrent administration of any other tumor therapy
• to be pregnant
• to have poorly controlled diabetes mellitus
• to have serious concomitant disorders.